Skip to main content
OTCMKTS:MYDP

Dougherty's Pharmacy Competitors

$0.02
0.00 (0.00 %)
(As of 03/15/2021)
Add
Compare
Today's Range
$0.02
$0.02
50-Day Range
$0.02
$0.02
52-Week Range
$0.00
$0.02
Volume9,000 shs
Average Volume9,011 shs
Market Capitalization$346,470.00
P/E RatioN/A
Dividend YieldN/A
Beta3.68

Competitors

Dougherty's Pharmacy (OTCMKTS:MYDP) Vs. CVS, WBA, CVET, RAD, YI, and PETS

Should you be buying MYDP stock or one of its competitors? Companies in the industry of "drug stores & proprietary stores" are considered alternatives and competitors to Dougherty's Pharmacy, including CVS Health (CVS), Walgreens Boots Alliance (WBA), Covetrus (CVET), Rite Aid (RAD), 111 (YI), and PetMed Express (PETS).

Dougherty's Pharmacy (OTCMKTS:MYDP) and CVS Health (NYSE:CVS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Dougherty's Pharmacy and CVS Health, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dougherty's Pharmacy0000N/A
CVS Health03912.85

CVS Health has a consensus target price of $92.1429, indicating a potential upside of 9.34%. Given CVS Health's higher possible upside, analysts plainly believe CVS Health is more favorable than Dougherty's Pharmacy.

Risk & Volatility

Dougherty's Pharmacy has a beta of 3.68, indicating that its share price is 268% more volatile than the S&P 500. Comparatively, CVS Health has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.

Insider & Institutional Ownership

0.5% of Dougherty's Pharmacy shares are owned by institutional investors. Comparatively, 74.2% of CVS Health shares are owned by institutional investors. 31.6% of Dougherty's Pharmacy shares are owned by insiders. Comparatively, 0.5% of CVS Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Dougherty's Pharmacy and CVS Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dougherty's PharmacyN/AN/AN/A
CVS Health2.99%15.60%4.52%

Valuation & Earnings

This table compares Dougherty's Pharmacy and CVS Health's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dougherty's Pharmacy$36.05 million0.01$-3,530,000.00N/AN/A
CVS Health$256.78 billion0.43$6.63 billion$7.0811.90

CVS Health has higher revenue and earnings than Dougherty's Pharmacy.

Summary

CVS Health beats Dougherty's Pharmacy on 10 of the 12 factors compared between the two stocks.

Walgreens Boots Alliance (NASDAQ:WBA) and Dougherty's Pharmacy (OTCMKTS:MYDP) are both retail/wholesale companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.

Profitability

This table compares Walgreens Boots Alliance and Dougherty's Pharmacy's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Walgreens Boots Alliance0.33%18.33%4.71%
Dougherty's PharmacyN/AN/AN/A

Insider & Institutional Ownership

56.0% of Walgreens Boots Alliance shares are owned by institutional investors. Comparatively, 0.5% of Dougherty's Pharmacy shares are owned by institutional investors. 16.9% of Walgreens Boots Alliance shares are owned by company insiders. Comparatively, 31.6% of Dougherty's Pharmacy shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Walgreens Boots Alliance and Dougherty's Pharmacy's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Walgreens Boots Alliance$139.54 billion0.34$456 million$4.7411.42
Dougherty's Pharmacy$36.05 million0.01$-3,530,000.00N/AN/A

Walgreens Boots Alliance has higher revenue and earnings than Dougherty's Pharmacy.

Volatility and Risk

Walgreens Boots Alliance has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500. Comparatively, Dougherty's Pharmacy has a beta of 3.68, suggesting that its stock price is 268% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Walgreens Boots Alliance and Dougherty's Pharmacy, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Walgreens Boots Alliance210202.00
Dougherty's Pharmacy0000N/A

Walgreens Boots Alliance currently has a consensus price target of $50.25, indicating a potential downside of 7.19%. Given Walgreens Boots Alliance's higher possible upside, research analysts plainly believe Walgreens Boots Alliance is more favorable than Dougherty's Pharmacy.

Summary

Walgreens Boots Alliance beats Dougherty's Pharmacy on 9 of the 11 factors compared between the two stocks.

Covetrus (NASDAQ:CVET) and Dougherty's Pharmacy (OTCMKTS:MYDP) are both computer and technology companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Insider and Institutional Ownership

94.1% of Covetrus shares are held by institutional investors. Comparatively, 0.5% of Dougherty's Pharmacy shares are held by institutional investors. 1.2% of Covetrus shares are held by company insiders. Comparatively, 31.6% of Dougherty's Pharmacy shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Covetrus and Dougherty's Pharmacy's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Covetrus$3.98 billion0.87$-1,019,000,000.00$0.7931.96
Dougherty's Pharmacy$36.05 million0.01$-3,530,000.00N/AN/A

Dougherty's Pharmacy has lower revenue, but higher earnings than Covetrus.

Analyst Ratings

This is a summary of current ratings and target prices for Covetrus and Dougherty's Pharmacy, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Covetrus01302.75
Dougherty's Pharmacy0000N/A

Covetrus currently has a consensus price target of $33.25, indicating a potential upside of 31.68%. Given Covetrus' higher possible upside, equities analysts clearly believe Covetrus is more favorable than Dougherty's Pharmacy.

Volatility and Risk

Covetrus has a beta of 2.28, suggesting that its stock price is 128% more volatile than the S&P 500. Comparatively, Dougherty's Pharmacy has a beta of 3.68, suggesting that its stock price is 268% more volatile than the S&P 500.

Profitability

This table compares Covetrus and Dougherty's Pharmacy's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Covetrus-1.21%7.09%2.63%
Dougherty's PharmacyN/AN/AN/A

Summary

Covetrus beats Dougherty's Pharmacy on 7 of the 11 factors compared between the two stocks.

Rite Aid (NYSE:RAD) and Dougherty's Pharmacy (OTCMKTS:MYDP) are both small-cap retail/wholesale companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Valuation & Earnings

This table compares Rite Aid and Dougherty's Pharmacy's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rite Aid$21.93 billion0.04$-452,170,000.00$0.15113.67
Dougherty's Pharmacy$36.05 million0.01$-3,530,000.00N/AN/A

Dougherty's Pharmacy has lower revenue, but higher earnings than Rite Aid.

Insider & Institutional Ownership

52.3% of Rite Aid shares are held by institutional investors. Comparatively, 0.5% of Dougherty's Pharmacy shares are held by institutional investors. 1.5% of Rite Aid shares are held by company insiders. Comparatively, 31.6% of Dougherty's Pharmacy shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Rite Aid and Dougherty's Pharmacy's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rite Aid-1.66%2.12%0.14%
Dougherty's PharmacyN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Rite Aid and Dougherty's Pharmacy, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rite Aid12001.67
Dougherty's Pharmacy0000N/A

Rite Aid presently has a consensus target price of $16.6667, indicating a potential downside of 2.25%. Given Rite Aid's higher possible upside, analysts plainly believe Rite Aid is more favorable than Dougherty's Pharmacy.

Volatility and Risk

Rite Aid has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, Dougherty's Pharmacy has a beta of 3.68, meaning that its stock price is 268% more volatile than the S&P 500.

Summary

Rite Aid beats Dougherty's Pharmacy on 6 of the 10 factors compared between the two stocks.

111 (NASDAQ:YI) and Dougherty's Pharmacy (OTCMKTS:MYDP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Profitability

This table compares 111 and Dougherty's Pharmacy's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
111-8.81%-67.04%-29.26%
Dougherty's PharmacyN/AN/AN/A

Analyst Ratings

This is a summary of current ratings for 111 and Dougherty's Pharmacy, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
11100103.00
Dougherty's Pharmacy0000N/A

111 presently has a consensus target price of $16.00, indicating a potential upside of 64.78%. Given 111's higher possible upside, equities research analysts clearly believe 111 is more favorable than Dougherty's Pharmacy.

Insider and Institutional Ownership

3.8% of 111 shares are owned by institutional investors. Comparatively, 0.5% of Dougherty's Pharmacy shares are owned by institutional investors. 31.6% of Dougherty's Pharmacy shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares 111 and Dougherty's Pharmacy's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
111$567.68 million1.41$-71,760,000.00($0.86)-11.29
Dougherty's Pharmacy$36.05 million0.01$-3,530,000.00N/AN/A

Dougherty's Pharmacy has lower revenue, but higher earnings than 111.

Volatility and Risk

111 has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Comparatively, Dougherty's Pharmacy has a beta of 3.68, meaning that its stock price is 268% more volatile than the S&P 500.

Summary

Dougherty's Pharmacy beats 111 on 6 of the 11 factors compared between the two stocks.

PetMed Express (NASDAQ:PETS) and Dougherty's Pharmacy (OTCMKTS:MYDP) are both small-cap retail/wholesale companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares PetMed Express and Dougherty's Pharmacy's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PetMed Express9.82%22.79%19.17%
Dougherty's PharmacyN/AN/AN/A

Valuation and Earnings

This table compares PetMed Express and Dougherty's Pharmacy's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PetMed Express$284.13 million1.98$25.85 millionN/AN/A
Dougherty's Pharmacy$36.05 million0.01$-3,530,000.00N/AN/A

PetMed Express has higher revenue and earnings than Dougherty's Pharmacy.

Insider and Institutional Ownership

91.6% of PetMed Express shares are held by institutional investors. Comparatively, 0.5% of Dougherty's Pharmacy shares are held by institutional investors. 3.6% of PetMed Express shares are held by company insiders. Comparatively, 31.6% of Dougherty's Pharmacy shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for PetMed Express and Dougherty's Pharmacy, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PetMed Express00103.00
Dougherty's Pharmacy0000N/A

PetMed Express presently has a consensus target price of $41.00, suggesting a potential upside of 47.85%. Given PetMed Express' higher probable upside, equities research analysts clearly believe PetMed Express is more favorable than Dougherty's Pharmacy.

Risk and Volatility

PetMed Express has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Dougherty's Pharmacy has a beta of 3.68, suggesting that its share price is 268% more volatile than the S&P 500.

Summary

PetMed Express beats Dougherty's Pharmacy on 9 of the 11 factors compared between the two stocks.


Dougherty's Pharmacy Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
CVS Health logo
CVS
CVS Health
2.3$84.27flat$110.95 billion$256.78 billion13.93Analyst Report
Insider Selling
Walgreens Boots Alliance logo
WBA
Walgreens Boots Alliance
2.2$54.14flat$46.80 billion$139.54 billion108.28Analyst Report
Covetrus logo
CVET
Covetrus
1.8$25.25flat$3.45 billion$3.98 billion-45.09
Rite Aid logo
RAD
Rite Aid
0.8$17.05flat$939.49 million$21.93 billion-2.29
YI
111
1.3$9.71flat$799.71 million$567.68 million-11.03Upcoming Earnings
PetMed Express logo
PETS
PetMed Express
1.8$27.73flat$562.12 million$284.13 million18.49
Progressive Care logo
RXMD
Progressive Care
0.0$0.08flat$42.34 million$32.63 million0.00Upcoming Earnings
Gap Down
CJJD
China Jo-Jo Drugstores
0.5$0.91flat$37.99 million$117.33 million-7.58
HealthWarehouse.com logo
HEWA
HealthWarehouse.com
0.4$0.18flat$9.37 million$15.76 million0.00
China Dasheng Biotechnology logo
CDBT
China Dasheng Biotechnology
0.0$0.03flat$0.00N/A0.00Gap Up
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.